Resource Center
Explore Resource Types
Focused Solutions
Biologics
Make advancements with precision biologics tools, designed to enhance your therapeutic approaches encompassing monoclonal antibodies, recombinant proteins, vaccines, and targeted next-generation cell and gene therapies.
Cell and Gene Therapy
The recent success of cell and gene therapies has paved the way for the next generation of advanced therapeutics. While challenges remain, cell and gene therapy research is seeing a transformational shift in the way that novel modalities, such as CAR-T, CRISPR, and vectors, are developed and delivered.
Disease Research
New drug modalities and targets are enabling us to live longer and healthier lives— but their development is grounded on a deep understanding of disease onset and progression.
Drug Development
The process of drug development comprises all the activities involved in bringing a new drug to market once a lead compound has been identified.
Functional Genomic Screening
Identify and characterize drug discovery targets with functional genomic screening services. Offering CRISPR knockout, CRISPR activation, CRISPR inhibition, dual screening and RNAi technologies
Integrated Lab Automation
From cellular screening and imaging applications to high-throughput screening and genomics-based applications, custom explorer™ G3 integrated workstations
Physiological Model Solutions
Drug discovery endeavors require a deep understanding of biological systems and their response to potential therapeutics.
Precision Medicine Research
Countless diseases, especially cancer, are highly heterogenous in nature which means a one-drug-fitsall approach isn’t practical for treating or fighting these diseases effectively.
Small Molecule Drug Discovery
With decades of experience in drug discovery driven by strong customer relationships, Revvity has developed an excellent product portfolio of drug discovery tools for complete solutions serving all parts of the discovery workflow.
All Resources
Filters
253 - 264 of 1186 Results
Murine NASH model could provide insights into NASH development and progression
Expert interview: recapitulating the blood-brain barrier using in vitro hiPSC models in drug discovery
Application of Whole Exome sequencing in identifying sequence variants and copy number variants in phenotypic females with disorders of sexual development (DSD)
Experience from the First 330 Cases of Low Pass Genome Sequencing (5X) Demonstrates Clinical Utility and Provides Potential Alternative to Traditional Microarray in the Clinical Settings
Sequencing of entire 2.2 MB DMD gene facilitates diagnostic testing and aids selection of patients for therapeutic intervention
Identification and accurate sizing of D4Z4 repeat units in patients suspected of facioscapulohumeral muscular dystrophy (FSHD) using optical genome mapping
Molecular Diagnosis of Facioscapulohumeral Muscular Dystrophy (FSHD) using Optical Genome Mapping
California Department of Public Health lab license
Measuring of Non-reducing Terminal Glycosaminoglycan Fragments increases specificity and differentiates Mucopolysaccharidosis Type I (MPS I) from Mucopolysaccharidosis Type II (MPS II)
Insights Derived From The First 500+ Clinical Cases Run Utilizing Low Pass Genome Sequencing (LP-GS) As An Alternative To Traditional Microarray
Newborn Screening Second Tier Molecular Testing for Lysosomal Storage Diseases and X-linked Adrenoleukodystrophy is Critical for Identifying True Positives
Utilization of Whole Genome Sequencing to Improve Diagnostic Yield in Patients with a Suspected Genetic Disorder(s)
Looking for technical documents?
Find the technical documents you need, ASAP, in our easy-to-search library.